Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients-Reference-Cited by-同舟云学术

Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients

Published:2018-12 Issue:6 Volume:57 Page:752-755
ISSN:1473-0502
Container-title:Transfusion and Apheresis Science
language:en
Short-container-title:Transfusion and Apheresis Science

Author:

Ciftciler Rafiye,Demiroglu Haluk,Buyukasık Yahya,Okay Mufide,Aksu Salih,Sayınalp Nilgun,Malkan Umit Yavuz,Haznedaroglu Ibrahim Celalettin,Ozcebe Osman,Goker Hakan

Publisher

Elsevier BV

Subject

Hematology

Reference18 articles.

1. Anthracycline dose intensification in acute myeloid leukemia;Fernandez;N Engl J Med,2009

2. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia;Cassileth;J Clin Oncol,1988

3. Intensive postremission chemotherapy in adults with acute myeloid leukemia;Mayer;N Engl J Med,1994

4. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia;Wiernik;Blood,1992

5. Toxicity and response criteria of the eastern cooperative oncology group;Oken;Am J Clin Oncol,1982

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?;Therapeutic Advances in Hematology;2021-01

2. Pharmacological strategies to overcome treatment resistance in acute myeloid leukemia: increasing leukemic drug exposure by targeting the resistance factor SAMHD1 and the toxicity factor Top2β;Expert Opinion on Drug Discovery;2020-08-31

3. Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2019-11